What question did this study set out to answer?

To evaluate the clinical utility of NGS-based measurable residual disease testing for B-cell acute lymphoblastic leukaemia.

February 22, 2026

Ultrasensitive next-generation sequencing-based clonality assay for disease monitoring in B-cell acute lymphoblastic leukaemia

Key Points

To evaluate the clinical utility of NGS-based measurable residual disease testing for B-cell acute lymphoblastic leukaemia.
Implemented NGS-based MRD testing since 2018.
Utilized in routine patient care for monitoring.
Focused on patients with B-cell acute lymphoblastic leukaemia.
Demonstrated clinical utility for disease monitoring.
Established effectiveness in detecting measurable residual disease.

Abstract

Background: Next-generation sequencing (NGS)-based measurable residual disease (MRD) testing is increasingly adopted in routine patient care for acute lymphoblastic leukaemia (ALL). We have successfully implemented NGS-based MRD testing since 2018 and demonstrated its clinical utility in B-cell acute lymphoblastic leukaemia (B-ALL).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Le et al. (Sun,) studied this question.

synapsesocial.com/papers/699a534bfdaf4e3c1268ee30 — DOI: https://doi.org/10.1016/j.pathol.2026.01.243

Authors

Anita Le

Wendi Lin

Austin Hospital

Gareth Lamb

Journals

Pathology

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Ultrasensitive next-generation sequencing-based clonality assay for disease monitoring in B-cell acute lymphoblastic leukaemia

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion